Empagliflozin to reduce inflammation after coronary stenting
Official title: Randomized Trial to Evaluate the Anti-inflammatory Effects of Empagliflozin Following PCI
Run by Hotel Dieu de France Hospital · NCT07292909 · Data updated 2026-11-12
This trial will test whether taking empagliflozin for three days before elective PCI reduces the rise in C‑reactive protein and other inflammatory markers in people with stable coronary artery disease.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Hotel Dieu de France Hospital Academic / other |
| Locations | 1 site (Beirut, Beirut) |
| Status | Recruiting |
| Started | September 1, 2025 |
| Main results expected | June 30, 2027 |
| Study ends | September 30, 2027 |
| Registry record updated | December 18, 2025 |
| Trial ID | NCT07292909 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with stable coronary artery disease scheduled for elective PCI on a native de novo coronary lesion who are not currently taking an SGLT2 inhibitor and have adequate kidney function.
✕Probably not a fit
Patients with recent acute coronary syndrome, active inflammatory or infectious disease, recent SGLT2 inhibitor use, creatinine clearance <30 mL/min, interventions on restenotic lesions or grafts, or those requiring complex devices are unlikely to be eligible or to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with stable coronary artery disease scheduled for elective percutaneous coronary intervention (PCI) will receive either empagliflozin or a matching placebo for three days before the procedure. Blood will be drawn before the intervention and again 24 hours after stenting to measure C‑reactive protein and other inflammatory markers. The primary goal is to see if empagliflozin blunts the post‑procedural rise in CRP compared with placebo. Key exclusions include recent SGLT2 inhibitor use, active inflammatory disease or infection, recent acute coronary syndrome, severe renal impairment, and procedures requiring specialized devices.
Why it matters
Potential benefit: If successful, this could show empagliflozin reduces periprocedural inflammation after stenting and help explain some cardiovascular benefits beyond blood sugar lowering.
How similar studies have gone: Large outcome trials have shown empagliflozin improves heart failure and cardiovascular outcomes and smaller clinical and preclinical studies suggest anti‑inflammatory effects, but using peri‑PCI CRP rise as a test of this effect is a relatively novel application.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Patients with stable CAD who are electively scheduled for PCI on a de novo lesion in a native coronary artery Exclusion Criteria: * • Patients who have been taking an SGLT-2 inhibitor during the last month * Patients who are receiving any anti-inflammatory medication: immunosuppressor, steroids, NSAID… * Patients who have underlying inflammatory conditions such as rheumatic arthritis, infection, active malignancy * Patients with an acute coronary syndrome within the last month * Intervention on a restenotic lesion or lesion in a saphenous vein graft * Creatinine clearance less than 30 mL/min * Patients who are treated with devices other than balloons and stents (lithotripsy, rotational atherectomy…)
Where it's running
-
Hotel Dieu de France
Beirut, Beirut, Lebanon Recruiting
Study contacts
- Principal investigator: Rabih R Azar, MD, MPH — Hotel Dieu de Frace
- Study coordinator: Rabih R Azar, MD, MPH
- Email: razarmd@hotmail.com
- Phone: +9613590999
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SiroMax sirolimus-coated balloon for small coronary vessels with or without prior stents
A first-in-human test to see if the SiroMax drug-coated balloon can safely open narrow coronary arteries in adults with or without prior stents.
-
Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease
This registry tests whether delivery time and inflation duration of drug-coated balloons affect outcomes in adults undergoing PCI for new coronary lesions.
-
Canagliflozin added to immunotherapy for advanced solid tumors
This study tests whether adding canagliflozin to tislelizumab-based immunotherapy helps people with unresectable or metastatic solid tumors.
-
Does extra family income improve child mental health and brain biology in low-income families?
This study tests whether three years of extra income for parents can improve their child’s mental health and neuroimmune function.
-
FDG PET/MRI to Find Painful Inflammation in the Patellofemoral Joint
This study tests whether FDG PET/MRI can locate inflammation causing knee pain in people with patellofemoral joint osteoarthritis.
-
Predicting major heart problems after coronary artery bypass grafting in people with heart failure
This study will test whether a blood marker called GDF-15 taken before bypass surgery can help predict major heart events over the year after CABG in patients with chronic heart failure and coronary artery disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.